R01CA271532

Multichannel Fluorescence Guided Surgery Tools Enabling Simultaneous Cancer Margin and Nerve Visualization in Prostatectomy - Project Summary

Prostate cancer is the most prevalent cancer in men and the second leading cause of cancer death. Prostatectomy is one of the most common primary treatments for prostate cancer, where surgeons face two main goals: prostate cancer cure and nerve preservation. However, with little visual acuity for nerve plexus recognition and conclusive cancer delineation, ideal outcomes for patients continue to challenge even experienced surgeons. Positive surgical margins and nerve damage occur in up to 21 and 60% of patients, respectively, resulting in poor cancer control as well as incontinence and impotence severely affecting post-operative quality of life.

No clinically approved methods exist to enhance direct cancer or nerve plexus visualization intraoperatively. Thus, technology to enable the direct visualization of cancer tissue and nerves simultaneously in real time would greatly reduce associated comorbidities and significantly improve prostatectomy outcomes. Fluorescence guided surgery (FGS) has successfully integrated into clinical medicine with only two FDA-approved fluorophores, providing surgeons real-time visualization. FGS systems operate mainly at near infrared (NIR, 700-900 nm) wavelengths, where tissue chromophore absorbance, autofluorescence, and scatter fall to local minima, allowing high contrast imaging at up to centimeter depths.

A number of targeted NIR contrast agents are under development, including nerve- and prostate-specific probes that together would provide an integrated FGS tool for prostatectomy. In the US, over 80% of prostatectomies are performed using robotic-assistance, where the da Vinci surgical robot (Intuitive Surgical) is the most common and is equipped standard with a NIR fluorescence-imaging channel capable of real-time visualization. Herein, we will collaborate with Drs. Jonathan Sorger (Intuitive Surgical) and Scott Davis (Dartmouth) to develop a multicolor FGS solution for prostatectomy that highlights both cancer and nerve tissues to improve patient outcomes.

Prostate specific membrane antigen (PSMA) is overexpressed in the majority of prostate cancers making it a promising target for prostate cancer imaging. A handful of molecules have shown high affinity for PSMA following labeling, which have been extensively investigated, where 800 nm PSMA targeted IS-002 has successfully completed phase I clinical trials sponsored by Intuitive Surgical. Herein, we will develop a NIR, spectrally-distinct, nerve-specific fluorophore for co-administration with PSMA-targeted IS-002 to bring this new FGS paradigm to prostate cancer patients.

In exciting preliminary work, our team has synthesized NIR nerve-specific fluorophores that can be imaged with clinical FGS systems. Herein, 700 nm NIR nerve-specific probes will be synthetically tuned for co-administration with PSMA-specific 800 nm IS-002 and validated for future translation to guided prostatectomy. These goals will be accomplished through the following specific aims:

Aim 1: Synthesize 700 nm NIR nerve-specific FGS probes.

Aim 2: Quantify preclinical pharmacology and toxicology of NIR nerve-specific probes co-administered with IS-002.

Aim 3: Select a lead nerve-specific probe for co-administration with IS-002 through demonstration of nerve- and prostate cancer-specific contrast.

Oregon Health & Science University

TO IMPROVE SCREENING AND EARLY DETECTION STRATEGIES AND TO DEVELOP ACCURATE DIAGNOSTIC TECHNIQUES AND METHODS FOR PREDICTING THE COURSE OF DISEASE IN CANCER PATIENTS. SCREENING AND EARLY DETECTION RESEARCH INCLUDES DEVELOPMENT OF STRATEGIES TO DECREASE CANCER MORTALITY BY FINDING TUMORS EARLY WHEN THEY ARE MORE AMENABLE TO TREATMENT. DIAGNOSIS RESEARCH FOCUSES ON METHODS TO DETERMINE THE PRESENCE OF A SPECIFIC TYPE OF CANCER; TO PREDICT ITS COURSE AND RESPONSE TO THERAPY, BOTH A PARTICULAR THERAPY OR A CLASS OF AGENTS; AND TO MONITOR THE EFFECT OF THE THERAPY AND THE APPEARANCE OF DISEASE RECURRENCE. THESE METHODS INCLUDE DIAGNOSTIC IMAGING AND DIRECT ANALYSES OF SPECIMENS FROM TUMOR OR OTHER TISSUES. SUPPORT IS ALSO PROVIDED FOR ESTABLISHING AND MAINTAINING RESOURCES OF HUMAN TISSUE TO FACILITATE RESEARCH. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO EXPAND AND IMPROVE THE SBIR PROGRAM; TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT; TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT; AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS; TO FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS; TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT; AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.

93.394 - Cancer Detection and Diagnosis Research

National Cancer Institute (NCI) [HHS - NIH]

Portland, Oregon 972393011 United States

Single Zip Code

NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) (PA-20-185)

Amendment Since initial award the total obligations have increased 385% from $632,874 to $3,068,539.